FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384161810> ?p ?o ?g. }

• W4384161810 endingPage "123227" @default.
• W4384161810 startingPage "123227" @default.
• W4384161810 abstract "We have synthesized new lipidic prodrugs of diclofenac by grafting aliphatic chains (C10, C12, C16 and C18) to diclofenac through an ester bond. Their molecular formulas were confirmed through HR-MS and the formation of ester bond by FTIR and NMR spectroscopy. Nanoparticles of the different prodrugs were successfully formulated using emulsion evaporation method and DSPE-PEG2000 as the only excipient. All nanoparticles were spherical and had a size between 110 and 150 nm, PdI ≤ 0.2 and negative Zeta potential values from −30 to −50 mV. In addition, they were stable upon storage at 4 °C up to 30–35 days. The encapsulation efficiency of the prodrug was above 90 % independently of the aliphatic chain length grafted. Nanoparticles did not induce any toxicity on LPS-activated THP-1 cells up to a concentration of 100 μg/mL (equivalent diclofenac) whereas diclofenac sodium salt IC50 was around 20 μg/mL. Following incubation of nanoparticles with LPS-activated THP-1 cells, a dose dependent inhibition of TNF-α was observed comparable to standard diclofenac sodium. Based on in vitro studies representative nanoparticles, Prodrug 3 NPs (C16 aliphatic chain) were selected for further in vitro and in vivo studies. Upon incubation in murine plasma, Prodrug 3 NPs underwent an enzymatic cleavage and almost 70 % of diclofenac was released from nanoparticles in 8 h. In vivo studies on a collagen induced arthritis murine model showed contrasted results: on one hand Prodrug 3 NPs led to a significant decrease of arthritis score and of paw volume compared to PBS after the second injection, on the other hand the third injection induced an important hepatic toxicity with the death of half of the mice from the NP group. To promote the reduction of inflammation while avoiding hepatic toxicity using NPs would require to precisely study the No Observable Adverse Effect Level and the schedule of administration in the future." @default.
• W4384161810 created "2023-07-14" @default.
• W4384161810 creator A5001413544 @default.
• W4384161810 creator A5017993242 @default.
• W4384161810 creator A5019974019 @default.
• W4384161810 creator A5025199996 @default.
• W4384161810 creator A5034493531 @default.
• W4384161810 creator A5040577138 @default.
• W4384161810 creator A5045035076 @default.
• W4384161810 creator A5046927736 @default.
• W4384161810 creator A5058791776 @default.
• W4384161810 creator A5062944646 @default.
• W4384161810 creator A5065609101 @default.
• W4384161810 creator A5069710348 @default.
• W4384161810 creator A5087660032 @default.
• W4384161810 date "2023-08-01" @default.
• W4384161810 modified "2023-09-27" @default.
• W4384161810 title "Diclofenac prodrugs nanoparticles: An alternative and efficient treatment for rheumatoid arthritis?" @default.
• W4384161810 cites W1992011164 @default.
• W4384161810 cites W2001141315 @default.
• W4384161810 cites W2033328636 @default.
• W4384161810 cites W2037010889 @default.
• W4384161810 cites W2039898739 @default.
• W4384161810 cites W2046680359 @default.
• W4384161810 cites W2050838462 @default.
• W4384161810 cites W2088144350 @default.
• W4384161810 cites W2114611409 @default.
• W4384161810 cites W2114914776 @default.
• W4384161810 cites W2122165212 @default.
• W4384161810 cites W2126429231 @default.
• W4384161810 cites W2128775174 @default.
• W4384161810 cites W2165278773 @default.
• W4384161810 cites W2169868751 @default.
• W4384161810 cites W2298332245 @default.
• W4384161810 cites W2321741169 @default.
• W4384161810 cites W2603931856 @default.
• W4384161810 cites W2618599149 @default.
• W4384161810 cites W2811162306 @default.
• W4384161810 cites W2909814895 @default.
• W4384161810 cites W2924324261 @default.
• W4384161810 cites W2947374783 @default.
• W4384161810 cites W3006490469 @default.
• W4384161810 cites W3175782107 @default.
• W4384161810 cites W4200497889 @default.
• W4384161810 doi "https://doi.org/10.1016/j.ijpharm.2023.123227" @default.
• W4384161810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37453671" @default.
• W4384161810 hasPublicationYear "2023" @default.
• W4384161810 type Work @default.
• W4384161810 citedByCount "0" @default.
• W4384161810 crossrefType "journal-article" @default.
• W4384161810 hasAuthorship W4384161810A5001413544 @default.
• W4384161810 hasAuthorship W4384161810A5017993242 @default.
• W4384161810 hasAuthorship W4384161810A5019974019 @default.
• W4384161810 hasAuthorship W4384161810A5025199996 @default.
• W4384161810 hasAuthorship W4384161810A5034493531 @default.
• W4384161810 hasAuthorship W4384161810A5040577138 @default.
• W4384161810 hasAuthorship W4384161810A5045035076 @default.
• W4384161810 hasAuthorship W4384161810A5046927736 @default.
• W4384161810 hasAuthorship W4384161810A5058791776 @default.
• W4384161810 hasAuthorship W4384161810A5062944646 @default.
• W4384161810 hasAuthorship W4384161810A5065609101 @default.
• W4384161810 hasAuthorship W4384161810A5069710348 @default.
• W4384161810 hasAuthorship W4384161810A5087660032 @default.
• W4384161810 hasBestOaLocation W43841618102 @default.
• W4384161810 hasConcept C108215921 @default.
• W4384161810 hasConcept C13965031 @default.
• W4384161810 hasConcept C150903083 @default.
• W4384161810 hasConcept C155672457 @default.
• W4384161810 hasConcept C171250308 @default.
• W4384161810 hasConcept C178790620 @default.
• W4384161810 hasConcept C185592680 @default.
• W4384161810 hasConcept C192562407 @default.
• W4384161810 hasConcept C207001950 @default.
• W4384161810 hasConcept C2778123984 @default.
• W4384161810 hasConcept C2779826273 @default.
• W4384161810 hasConcept C2908765736 @default.
• W4384161810 hasConcept C43617362 @default.
• W4384161810 hasConcept C55493867 @default.
• W4384161810 hasConcept C71240020 @default.
• W4384161810 hasConcept C71924100 @default.
• W4384161810 hasConcept C86181022 @default.
• W4384161810 hasConcept C86803240 @default.
• W4384161810 hasConcept C98274493 @default.
• W4384161810 hasConceptScore W4384161810C108215921 @default.
• W4384161810 hasConceptScore W4384161810C13965031 @default.
• W4384161810 hasConceptScore W4384161810C150903083 @default.
• W4384161810 hasConceptScore W4384161810C155672457 @default.
• W4384161810 hasConceptScore W4384161810C171250308 @default.
• W4384161810 hasConceptScore W4384161810C178790620 @default.
• W4384161810 hasConceptScore W4384161810C185592680 @default.
• W4384161810 hasConceptScore W4384161810C192562407 @default.
• W4384161810 hasConceptScore W4384161810C207001950 @default.
• W4384161810 hasConceptScore W4384161810C2778123984 @default.
• W4384161810 hasConceptScore W4384161810C2779826273 @default.
• W4384161810 hasConceptScore W4384161810C2908765736 @default.
• W4384161810 hasConceptScore W4384161810C43617362 @default.
• W4384161810 hasConceptScore W4384161810C55493867 @default.
• W4384161810 hasConceptScore W4384161810C71240020 @default.

• next